Cellectis SA (NASDAQ:CLLS) shares saw unusually-strong trading volume on Tuesday . Approximately 178,055 shares traded hands during trading, an increase of 107% from the previous session’s volume of 85,983 shares.The stock last traded at $26.67 and had previously closed at $26.65.

Several equities research analysts have issued reports on CLLS shares. Piper Jaffray Cos. reissued a “buy” rating on shares of Cellectis SA in a research note on Sunday, May 8th. Zacks Investment Research cut Cellectis SA from a “hold” rating to a “sell” rating in a research note on Thursday, May 12th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Cellectis SA in a research note on Tuesday, May 31st. Finally, Jefferies Group reissued a “buy” rating on shares of Cellectis SA in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $43.60.

The stock’s market capitalization is $953.97 million. The company has a 50-day moving average of $26.53 and a 200-day moving average of $27.19.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.